Alzheimer’s Disease Progress: Latest Updates from Japan
- The fight against Alzheimer's disease has seen notable, though incremental, progress in recent years.
- It requires regular infusions and carries risks of side effects, including amyloid-related imaging abnormalities (ARIA), which can cause brain swelling or bleeding.
- For decades,the "amyloid hypothesis" - the idea that amyloid plaques are the primary driver of Alzheimer's - has dominated research.
Progress in Alzheimer’s Disease research: A Shifting Landscape
Table of Contents
Updated September 20, 2025
Recent breakthroughs and Approvals
The fight against Alzheimer’s disease has seen notable, though incremental, progress in recent years. In July 2023, the U.S. Food and drug Administration (FDA) granted traditional approval to Leqembi (lecanemab), an antibody therapy designed to remove amyloid plaques from the brain – a hallmark of Alzheimer’s. This followed earlier accelerated approval and represents a significant step, as it targets the underlying pathology of the disease rather then just managing symptoms.
However, Leqembi is not without limitations. It requires regular infusions and carries risks of side effects, including amyloid-related imaging abnormalities (ARIA), which can cause brain swelling or bleeding. Its clinical benefit, while statistically significant in slowing cognitive decline, is modest, typically slowing decline by 27% over 18 months in clinical trials.
The Amyloid Hypothesis and Beyond
For decades,the “amyloid hypothesis” – the idea that amyloid plaques are the primary driver of Alzheimer’s – has dominated research. Leqembi’s approval lends support to this theory, but it’s increasingly clear that Alzheimer’s is a multifaceted disease. Research is expanding to investigate other contributing factors, including tau tangles, inflammation, vascular issues, and genetic predispositions.
Donanemab, another amyloid-targeting antibody developed by Eli Lilly, showed promising results in clinical trials, demonstrating a slightly greater slowing of cognitive decline than Leqembi in some patient groups. However, it also carries risks of ARIA and is currently under FDA review as of September 2025. NPR reported on the Donanemab trial results in December 2023,highlighting both its potential and the ongoing safety concerns.
Early Detection and Biomarkers
A crucial area of progress is in early detection. Blood tests capable of identifying biomarkers associated with amyloid and tau pathology are becoming more accurate and accessible. These tests, while not yet widely available for routine screening, offer the potential to identify individuals at risk *before* significant cognitive symptoms appear, allowing for earlier intervention and potentially more effective treatment. The Alzheimer’s Association provides detailed facts on the progress and use of these blood-based biomarkers.
PET scans and cerebrospinal fluid analysis remain established methods for detecting these biomarkers, but are more invasive and expensive than blood tests.
Challenges and Future Directions
Despite these advances, significant challenges remain. Alzheimer’s disease is complex, and current treatments are not a cure. They offer modest benefits and are most effective when administered in the early stages of the disease. Furthermore, access to these treatments can be limited by cost and the need for specialized medical facilities.
Future research is focused on developing more effective therapies, including those that target multiple pathways involved in the disease process. This includes exploring novel drug targets, gene therapies, and lifestyle interventions. Prevention strategies, such as managing cardiovascular risk factors and promoting brain health through diet and exercise, are also gaining increasing attention.